July 25, 2011

New Cancer Treatment Device Goes Into Service Today

MANCHESTER, England, July 25, 2011 /PRNewswire/ --

- Experts Welcome Latest Advance as Promising Development for UK

A treatment system called the Novalis(R) Tx(TM) has gone into service
today, which has the ability to destroy cancerous cells virtually anywhere
in the body in a single, 20-minute session, without the need for a single
cut of the scalpel.

The Novalis Tx, installed in The Christie at Salford Royal, a brand new
radiotherapy centre in the North West, treats cancer using a specialised
technique called radiosurgery which is especially beneficial for tumours of
the brain and spine previously thought untreatable by surgeons.

Using powerful, highly accurate beams of radiation shaped to fit the
precise shape of even the most complex tumours, the system is able to treat
painlessly without the need for invasive[1] surgery and with fewer side
effects. The short treatment times of the system benefit both doctor and
patient; and mean more patients can be treated on the system in one day.
Patients are often able to attend clinic just as an outpatient, returning to
life the same day. Frameless radiosurgery provides a patient-friendly
alternative to techniques that require immobilisation with an invasive head
ring that is affixed to the skull[1].

Rachel Good, Christie radiotherapy manager for the new centre, says:
"The Novalis Tx[TM] was the perfect choice for the centre because it will
help The Christie treat more patients by switching between specialised
radiosurgery for tumours in the brain to standard radiotherapy for other
cancers of the body. In our first year we are looking to treat 720 patients
with the Novalis Tx, 120 of which will be priority brain tumour patients
where precise, non-invasive treatment is particularly effective."

News will be welcomed by the 300,000 people in the UK diagnosed with
cancer each year[2]. Of these 50,000 people are estimated to develop either
primary or secondary brain tumours[3], where traditional treatment is
difficult to provide. Malignant primary brain tumours take more years off
the average person's life than any other cancer and are the most significant
cause of cancer death amongst men under 45 years and women under 35[1].

Ms Tina Karabatsou, Consultant Neurosurgeon at the Salford Royal NHS
Foundation Trust, says: "One of the fantastic advantages of the new Novalis
Tx treatment is we will be able to treat brain conditions we were previously
unable to treat; such as tumours really deep in the brain where open surgery
is too dangerous. Equally important is the non-invasive nature of treatment,
which means treatment sessions can be performed as an outpatient day-case
and with significantly less side effects."

The launch of the high-quality treatment coincides with new guidelines
released by the NHS National Cancer Action Team which state that
radiosurgery should be made available to all suitable cancer patients in
England. By the end of 2011 three sites will be treating with the Novalis Tx
developed by Varian Medical Systems and Brainlab in England and Scotland,
improving access to advanced cancer care to patients across the UK.

Helen Bulbeck, Director of patient charity Brainstrust, comments: "The
launch of the Novalis Tx system is a huge stride towards modernising cancer
care in the UK to levels seen in Europe and the US. This is a great
achievement for brain tumour treatment and one that we hope to see the NHS
continue to build on in the years to come."

Further information:

About Brainlab

Brainlab develops, manufactures and markets software-driven medical
technology that supports targeted, less-invasive treatment. Core products
are image-guided systems and software that provide real-time information
used for surgical navigation and radiosurgical planning and delivery.

Brainlab technology drives collaboration between hospitals and
clinicians from a wide variety of subspecialties-from neurosurgery and
oncology to orthopedics, ENT, CMF and spine and trauma. This integration
delivers better access to improved and more efficient treatment.

Founded in 1989, the privately held Brainlab group has more than 5,000
systems installed in over 80 countries. Based in Munich, Germany, Brainlab
employs 970 people in 16 offices worldwide.

To learn more, visit http://www.brainlab.com.

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's
leading manufacturer of medical devices and software for treating cancer and
other medical conditions with radiotherapy, radiosurgery, proton therapy,
and brachytherapy. The company supplies informatics software for managing
comprehensive cancer clinics, radiotherapy centres and medical oncology
practices. Varian is a premier supplier of tubes and digital detectors for
X-ray imaging in medical, scientific, and industrial applications and also
supplies X-ray imaging products for cargo screening and industrial
inspection. Varian Medical Systems employs approximately 5,100 people who
are located at manufacturing sites in North America, China, and Europe and
in its 79 sales and support offices around the world. For more information,
visit http://www.varian.com.

About The Christie Foundation Trust

The Christie is one of the leading cancer centres in Europe treating
about 40,000 patients every year and an international leader in research.

The new GBP18 million radiotherapy centre in Salford is part of a unique
network of Christie radiotherapy centres to bring treatment closer to
people's homes. As well as being equipped to deliver stereotactic
radiosurgery, a highly specialised neurosurgical technique for brain
conditions, the centre will be treating 60 patients a day from the local
area for the most common cancers like breast, bowel and lung.

About Salford Royal NHS Foundation Trust

Salford Royal NHS Foundation Trust is recognised as one of the best
Trust's in the NHS and aims to provide safe, clean and personal care to all
patients. Salford Royal is large teaching Trust providing a range of
medical, surgical, maternity and emergency services to the people of
Salford. The Trust also offers specialist care to people from all over the
UK who require expert tertiary help with, for example, neuroscience and
kidney conditions. On 1 April 2011, Salford Royal integrated with Salford
Community Health; the Trust now provides a range of community and primary
care services. Our core purpose is to provide clinical, academic and service
excellence ensuring the patient experience is at the forefront of care.


1. Some doctors may opt for a minamally invasive head frame depending on
the specific treatment and patient.

2. Cancer Research UK. Cancer incidence - UK statistics. 2007.
http://info.cancerresearchuk.org/cancerstats/incidence/ (Last accessed
18 Jul 2011)

3. Brain Tumour Research, Brain Tumour UK, International Brain Tumour
Alliance & Samantha Dickson Brain Tumour Trust. A manifesto for everyone
affected by a brain tumour.

SOURCE Brainlab